Katherine Wesseling

Summary

Affiliation: University of California
Country: USA

Publications

  1. Wesseling Perry K. FGF-23 in bone biology. Pediatr Nephrol. 2010;25:603-8 pubmed publisher
    ..Thus, dysregulation of osteocytic proteins occur very early in the course of CKD and appear to be central to altered bone and mineral metabolism in this patient population. ..
  2. Wesseling Perry K, Pereira R, Tseng C, Elashoff R, Zaritsky J, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:146-52 pubmed publisher
  3. Wesseling K, Bakkaloglu S, SALUSKY I. Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol. 2008;23:195-207 pubmed
  4. Wesseling Perry K, Tsai E, Ettenger R, Juppner H, Salusky I. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?. Nephrol Dial Transplant. 2011;26:3779-84 pubmed publisher
    ..FGF-23 levels may be associated with increased risk for deterioration of kidney function and episodes of rejection. ..
  5. Wesseling Perry K, Juppner H. The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications. Bone. 2013;54:222-9 pubmed publisher
    ..Further studies are critically needed to identify the initial trigger for abnormalities of skeletal mineralization and turnover as well as the potential effects that current therapeutic options may have on osteocyte biology. ..
  6. Wesseling Perry K. Defective skeletal mineralization in pediatric CKD. Curr Osteoporos Rep. 2015;13:98-105 pubmed publisher
    ..Further studies are critically needed to identify the initial trigger for abnormalities of skeletal mineralization as well as the potential effects that current therapeutic options may have on osteocyte biology and bone mineralization. ..
  7. Wesseling Perry K, Harkins G, Wang H, Sahney S, Gales B, Elashoff R, et al. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol. 2009;24:1355-61 pubmed publisher
    ..The PTH values obtained by first- and second-generation PTH-IMAs correlated closely throughout therapy and the response of PTH was similar to both PTH-IMAs, despite differences in serum calcium levels. ..
  8. Wesseling Perry K, Pereira R, Sahney S, Gales B, Wang H, Elashoff R, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79:112-9 pubmed publisher
    ..Sevelamer allows the use of higher doses of vitamin D. Implications of these changes on bone and cardiovascular biology remain to be established. ..
  9. Pereira R, Bischoff D, YAMAGUCHI D, Salusky I, Wesseling Perry K. Micro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry. Clin J Am Soc Nephrol. 2016;11:481-7 pubmed publisher
    ..Thus, bone mineralization may be accurately assessed by μCT of bone biopsy cores. Additional studies are warranted to define the value of high-resolution CT in the prediction of bone mineralization in vivo. ..

More Information

Publications12

  1. Wesseling Perry K, Pereira R, Wang H, Elashoff R, Sahney S, Gales B, et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009;94:511-7 pubmed publisher
    ..Together with other biomarkers, FGF-23 measurements may indicate skeletal mineralization status in this patient population. ..
  2. Wesseling Perry K. Osteocyte dysfunction and renal osteodystrophy: not just calcium and phosphorus anymore. Kidney Int. 2017;91:1276-1278 pubmed publisher
    ..These concepts may alter how the skeletal, cardiovascular, and infectious complications of chronic kidney disease are managed. ..
  3. Khouzam N, Wesseling Perry K. Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease. Pediatr Nephrol. 2017;: pubmed publisher